Nitin Jain
UT MD Anderson · M.D. Anderson Cancer Center · The University of Texas MD Anderson Cancer Center (MDACC)
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Nitin Jain as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:45 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07674810 · A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic LeukemiaM.D. Anderson Cancer Center · not yet recruiting · Chronic Lymphocytic Leukemia · principal investigator
- Ph1NCT07674823 · Study Of KITE-753 in R/R B-Cell ALLM.D. Anderson Cancer Center · not yet recruiting · B-cell Acute Lymphoblastic Leukemia · principal investigator
- Ph2NCT07508995 · A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL)M.D. Anderson Cancer Center · recruiting · Chronic Lymphocytic Leukemia (CLL) · principal investigator
- Ph1NCT05961696 · A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic LeukemiaM.D. Anderson Cancer Center · withdrawn · Refractory B-cell Acute Lymphoblastic Leukemia · principal investigator
- Ph2NCT05536349 · Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)M.D. Anderson Cancer Center · recruiting · Leukemia · principal investigator
- Ph1NCT05275504 · Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell MalignanciesTransThera Sciences (Nanjing), Inc. · unknown · B-Cell Malignancies · principal investigator
- Ph1NCT04865419 · Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological MalignanciesAstraZeneca · terminated · Haematological Malignancies · principal investigator
- N/ANCT04831164 · Genetic Epidemiology of Rotator Cuff Tears: The cuffGEN StudyUniversity of Michigan · recruiting · Rotator Cuff Tears · principal investigator
- Ph1NCT04781855 · Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter TransformationM.D. Anderson Cancer Center · withdrawn · Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma · principal investigator
- Ph1/Ph2NCT04150497 · Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)Cellectis S.A. · active not recruiting · B-cell Acute Lymphoblastic Leukemia · principal investigator
- Ph1/Ph2NCT03698552 · ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic LeukemiaM.D. Anderson Cancer Center · terminated · Blasts 5 Percent or More of Bone Marrow Nucleated Cells, CD22 Positive, Philadelphia Chromosome Positive · principal investigator
- Ph2NCT02846623 · Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter SyndromeM.D. Anderson Cancer Center · active not recruiting · Chronic Lymphocytic Leukemia, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia · principal investigator
- Ph2NCT02756897 · Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic LeukemiaM.D. Anderson Cancer Center · active not recruiting · Chronic Lymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma · principal investigator
- Ph2NCT02629809 · Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic LeukemiaM.D. Anderson Cancer Center · active not recruiting · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma · principal investigator
- Ph2NCT02481297 · Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) PatientsM.D. Anderson Cancer Center · completed · Leukemia, Chronic Lymphocytic Leukemia, Lymphocytic Leukemia · principal investigator
- Ph2NCT02420717 · Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic LeukemiaM.D. Anderson Cancer Center · terminated · Recurrent B Acute Lymphoblastic Leukemia, Recurrent Ph-Like Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia · principal investigator
- Ph2NCT02420938 · Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) PatientsM.D. Anderson Cancer Center · withdrawn · Leukemia · principal investigator
- Ph2NCT02420912 · Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter TransformationM.D. Anderson Cancer Center · completed · Loss of Chromosome 17p, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma · principal investigator
- Ph1/Ph2NCT02311998 · Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CMLM.D. Anderson Cancer Center · completed · B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blasts More Than 5 Percent of Bone Marrow Nucleated Cells · principal investigator
- Ph1/Ph2NCT02096042 · Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)M.D. Anderson Cancer Center · terminated · Leukemia · principal investigator
- Ph2NCT01907815 · Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid LeukemiaNational Cancer Institute (NCI) · terminated · Recurrent Adult Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia · principal investigator
- Ph1/Ph2NCT01794702 · Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute LeukemiaM.D. Anderson Cancer Center · completed · Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:45 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 3 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- The Genetic Epidemiology of Rotator Cuff Tears: the cuffGEN Study.R01AR074989 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · fiscal years 2020 to 2025 · $216,263 awarded in 2025Grant number is on one of their registry trials
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Experimental Medicine ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FUNDA MERIC-BERNSTAM · fiscal years 2013 to 2026Named on NCT02420717, NCT01907815
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:45 UTC. The ranking covers the 200 most relevant of 175 PubMed records, and a shared surname and initials can bring in a namesake. All 175 on PubMed
- Ibrutinib and Venetoclax for First-Line Treatment of CLL.N Engl J Med · 2019426 citationsRCR 15.0
- 324 citationsRCR 11.8
- Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.J Clin Oncol · 2021297 citationsRCR 16.3
- 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.Lancet Haematol · 2020282 citationsRCR 11.3
- Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma.N Engl J Med · 2021247 citationsRCR 17.3
- Antibiotic prophylaxis for percutaneous endoscopic gastrostomy. A prospective, randomized, double-blind clinical trial.Ann Intern Med · 1987245 citationsRCR 15.5
- Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial.Lancet Haematol · 2023236 citationsRCR 20.8
- 226 citationsRCR 8.0
- 221 citationsRCR 6.0
- 220 citationsRCR 6.7